Alastair David Griffiths Lawson
Alastair David Griffiths Lawson, Slough GB
Patent application number | Description | Published |
---|---|---|
20100158913 | Antibody Molecules Having Specificity for Human IL-1B - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 06-24-2010 |
20100254978 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 - The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 10-07-2010 |
20100260773 | ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13 - The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 10-14-2010 |
20110135662 | FUNCTION MODIFYING NAv 1.7 ANTIBODIES | 06-09-2011 |
20120183558 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 07-19-2012 |
20130330344 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 - The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 12-12-2013 |
20140065674 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 03-06-2014 |
20140178387 | ANTIBODY MOLECULES HAVING BINDING SPECIFICITY FOR HUMAN IL-13 - The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 06-26-2014 |
20140342406 | DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES | 11-20-2014 |
Alastair David Griffiths Lawson, Berkshire GB
Patent application number | Description | Published |
---|---|---|
20090075398 | Method for Obtaining Antibodies - A method of obtaining at least one recombinant antibody with improved affinity for a selected antigen from a family of antibodies which bind the selected antigen comprising: a) obtaining a family of two or more antibodies which bind the same antigen in which the VH CDR3 amino acid sequence of each antibody in the family is the same length and greater than 60% identical at the amino acid level; b) re-pairing the VH region of an antibody obtained in step (a) with the VL region from a different antibody obtained in step (a) to produce a new recombinant antibody; and c) screening the recombinant antibody produced in step (b) and selecting said antibody if it has improved affinity for the selected antigen compared to any one of the antibodies obtained in step (a). | 03-19-2009 |
20090123944 | Bioassays - The invention relates to vectors encoding bioassay receptors and in vitro bioassays using said bioassay receptors for assessing compounds of interest. In particular, the bioassays provide a generic platform for the comparison of binding of different ligands to their respective receptors or binding partners in the presence and/or absence of a compound of interest. | 05-14-2009 |
20090304696 | Single Chain FC Polypeptides - The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain. | 12-10-2009 |
20090326203 | Framework Selection - The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks. | 12-31-2009 |
20100093977 | Altered Antibodies - This invention relates to engineering of antibodies and more specifically provides altered antibodies of the IgG class to which one or more effector molecules are attached. The invention further relates to methods for the production of such conjugated antibodies. | 04-15-2010 |
20110275857 | Antibody-Guided Fragment Growth - The present invention relates to an improved method for drug discovery comprising using contact residue information derived from antibody-protein target interactions to help to direct the growth of small molecule fragments during the synthesis of a drug candidate. In particular, the present invention relates to the use of atomic structural information derived from anti-body-protein interactions to guide the growth of small molecular fragments during lead optimisation, thus generating small molecule compounds which can alter the biological activity of a target protein. | 11-10-2011 |
Alastair David Griffiths Lawson, Slough Berkshire GB
Patent application number | Description | Published |
---|---|---|
20090275056 | Methods for obtaining antibodies - The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen. | 11-05-2009 |
20130066054 | MULTIVALENT ANTIBODIES - A multivalent antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a variable domain nominally V | 03-14-2013 |
Alastair David Griffiths Lawson, Alresford GB
Patent application number | Description | Published |
---|---|---|
20120259096 | ANTIBODIES TO ION CHANNELS - An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies. | 10-11-2012 |